Galmed Pharmaceuticals Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 17.87 million compared to USD 32.47 million a year ago. Basic loss per share from continuing operations was USD 10.65 compared to USD 19.8 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3916 USD | -0.23% | +5.04% | -13.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.93% | 2.35M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- GLMD Stock
- News Galmed Pharmaceuticals Ltd.
- Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022